Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T Bridging to Allo-HSCT in R/R CD7+ Hematologic Malignancies
NCT05827835Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UTAA07 in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoint: Incidence and level of Adverse Events and Serious Adverse Events at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
UTAA07
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05827835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827835.